← Back to Treatments
🏅 FDA Orphan Designation

Yartemlea

narsoplimab-wuug

Manufacturer: Omeros Corporation

Indicated for:
Complications after hematopoietic stem cell transplantationOrphan

FDA-Approved Indications (1)

treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)

Indications & Usage

1 INDICATIONS AND USAGE YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 )

💙 Support Programs

View all →
YARTEMLEA
Novartis
Apply ↗
Yartemlea
Omeros Corporation

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.